Preserving Access to Orphan Drugs Act of 2018
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Dec 17, 2018)
Preserving Access to Orphan Drugs Act of 2018
This bill amends the Patient Protection and Affordable Care Act to expand the definition of orphan drug for purposes of the annual fee paid by brand name prescription drug manufacturers and importers to include medications for rare conditions that were, prior to 2011, approved or in clinical trials. (Drug manufacturers and importers pay an annual fee based on their sales of brand name prescription drugs, excluding sales of orphan drugs.)
What just happenedJan 2, 2019
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseDec 17, 2018
- Jan 2, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Dec 17, 2018IntroReferralH11100
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Dec 17, 2018IntroReferralH11100
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Dec 17, 2018IntroReferralIntro-H
Introduced in House
- Dec 17, 2018IntroReferral1000
Introduced in House